Cargando…
Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
BACKGROUND: N-1-(Deoxyfructosyl) valine (DFV) β-hemoglobin (β-Hb), commonly referred as HbA1c, is widely used diagnostic marker in diabetes, believed to provide glycemic status of preceding 90–120 days. However, the turnover of hemoglobin is about 120 days, the DFV-β-Hb, an early and reversible glyc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812615/ https://www.ncbi.nlm.nih.gov/pubmed/27030792 http://dx.doi.org/10.1186/s12014-016-9108-y |
_version_ | 1782424199468417024 |
---|---|
author | Jagadeeshaprasad, Mashanipalya G. Batkulwar, Kedar B. Meshram, Nishita N. Tiwari, Shalbha Korwar, Arvind M. Unnikrishnan, Ambika G. Kulkarni, Mahesh J. |
author_facet | Jagadeeshaprasad, Mashanipalya G. Batkulwar, Kedar B. Meshram, Nishita N. Tiwari, Shalbha Korwar, Arvind M. Unnikrishnan, Ambika G. Kulkarni, Mahesh J. |
author_sort | Jagadeeshaprasad, Mashanipalya G. |
collection | PubMed |
description | BACKGROUND: N-1-(Deoxyfructosyl) valine (DFV) β-hemoglobin (β-Hb), commonly referred as HbA1c, is widely used diagnostic marker in diabetes, believed to provide glycemic status of preceding 90–120 days. However, the turnover of hemoglobin is about 120 days, the DFV-β-Hb, an early and reversible glycation product eventually may undergo irreversible advanced glycation modifications such as carboxymethylation or carboxyethylation. Hence quantification of N-1-(carboxymethyl) valine (CMV) and N-1-(carboxyethyl) valine (CEV) peptides of β-Hb would be useful in assessing actual glycemic status. RESULTS: Fragment ion library for synthetically glycated peptides of hemoglobin was generated by using high resolution–accurate mass spectrometry (HR/AM). Using parallel reaction monitoring, deoxyfructosylated, carboxymethylated and carboxyethylated peptides of hemoglobin were quantified in clinical samples from healthy control, pre-diabetes, diabetes and poorly controlled diabetes. For the first time, we report N-1-β-valine undergoes carboxyethylation and mass spectrometric quantification of CMV and CEV peptides of β-hemoglobin. Carboxymethylation was found to be the most abundant modification of N-1-β-valine. Both CMV-β-Hb and CEV-β-Hb peptides showed better correlation with severity of diabetes in terms of fasting glucose, postprandial glucose and microalbuminuria. CONCLUSIONS: This study reports carboxymethylation as a predominant modification of N-1-β-valine of Hb, and quantification of CMV-β-Hb and CEV-β-Hb could be useful parameter for assessing the severity of diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9108-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4812615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48126152016-03-31 Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes Jagadeeshaprasad, Mashanipalya G. Batkulwar, Kedar B. Meshram, Nishita N. Tiwari, Shalbha Korwar, Arvind M. Unnikrishnan, Ambika G. Kulkarni, Mahesh J. Clin Proteomics Research BACKGROUND: N-1-(Deoxyfructosyl) valine (DFV) β-hemoglobin (β-Hb), commonly referred as HbA1c, is widely used diagnostic marker in diabetes, believed to provide glycemic status of preceding 90–120 days. However, the turnover of hemoglobin is about 120 days, the DFV-β-Hb, an early and reversible glycation product eventually may undergo irreversible advanced glycation modifications such as carboxymethylation or carboxyethylation. Hence quantification of N-1-(carboxymethyl) valine (CMV) and N-1-(carboxyethyl) valine (CEV) peptides of β-Hb would be useful in assessing actual glycemic status. RESULTS: Fragment ion library for synthetically glycated peptides of hemoglobin was generated by using high resolution–accurate mass spectrometry (HR/AM). Using parallel reaction monitoring, deoxyfructosylated, carboxymethylated and carboxyethylated peptides of hemoglobin were quantified in clinical samples from healthy control, pre-diabetes, diabetes and poorly controlled diabetes. For the first time, we report N-1-β-valine undergoes carboxyethylation and mass spectrometric quantification of CMV and CEV peptides of β-hemoglobin. Carboxymethylation was found to be the most abundant modification of N-1-β-valine. Both CMV-β-Hb and CEV-β-Hb peptides showed better correlation with severity of diabetes in terms of fasting glucose, postprandial glucose and microalbuminuria. CONCLUSIONS: This study reports carboxymethylation as a predominant modification of N-1-β-valine of Hb, and quantification of CMV-β-Hb and CEV-β-Hb could be useful parameter for assessing the severity of diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9108-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-29 /pmc/articles/PMC4812615/ /pubmed/27030792 http://dx.doi.org/10.1186/s12014-016-9108-y Text en © Jagadeeshaprasad et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jagadeeshaprasad, Mashanipalya G. Batkulwar, Kedar B. Meshram, Nishita N. Tiwari, Shalbha Korwar, Arvind M. Unnikrishnan, Ambika G. Kulkarni, Mahesh J. Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
title | Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
title_full | Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
title_fullStr | Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
title_full_unstemmed | Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
title_short | Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
title_sort | targeted quantification of n-1-(carboxymethyl) valine and n-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812615/ https://www.ncbi.nlm.nih.gov/pubmed/27030792 http://dx.doi.org/10.1186/s12014-016-9108-y |
work_keys_str_mv | AT jagadeeshaprasadmashanipalyag targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes AT batkulwarkedarb targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes AT meshramnishitan targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes AT tiwarishalbha targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes AT korwararvindm targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes AT unnikrishnanambikag targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes AT kulkarnimaheshj targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes |